According to Fortune Business Insights, the global blood collection devices market size 2026 was valued at USD 9.4 billion in 2025 and is projected to grow from USD 10.11 billion in 2026 to USD 18.07 billion by 2034, reflecting a compound annual growth rate of 7.53% over the forecast period. This growth trajectory is tied to expanding clinical testing volumes, rising screening for chronic conditions, and the broader push toward preventive healthcare worldwide.
Blood collection devices form a foundational part of diagnostic and therapeutic workflows in hospitals, laboratories, blood banks, and research institutions. The report notes that innovation in safety-engineered needles, vacuum collection tubes, and automated platforms continues to reshape how providers approach sample acquisition, while tightening infection-control regulations keep reinforcing long-term demand. The United States is described as the largest national market, owing to its advanced healthcare infrastructure, frequent diagnostic testing, and strict regulatory oversight of blood safety practices.
Regional Distribution
The report breaks down global market share by region as follows:
- North America: roughly 35%
- Europe: roughly 28%
- Asia-Pacific: roughly 25%
- Rest of the World: roughly 12%
Within Europe, Germany and the UK are highlighted as the leading contributors, while in Asia-Pacific, China and Japan account for the largest shares, reflecting their scale of healthcare infrastructure and diagnostic testing activity.
North America's leadership stems from its dense hospital and laboratory networks, established blood bank and plasma collection systems, and early adoption of digital tracking and closed-system collection technology. Europe's position is supported by universal healthcare coverage, an aging population, and standardized procurement practices across its public health systems. Asia-Pacific is positioned as the fastest-evolving region, driven by hospital construction, expanding diagnostic awareness, and rising chronic disease prevalence, particularly in China and Japan.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/blood-collection-devices-market-103500
Market Drivers, Restraints, Opportunities, and Challenges
The report frames market dynamics around four themes. The primary driver is the increasing global burden of chronic and infectious disease, which fuels demand for routine and specialized blood testing, alongside the expansion of biomarker-driven and personalized medicine. A key restraint is the high cost of regulatory compliance — sterility, labeling, and safety standards raise barriers for smaller manufacturers and slow the pace of new product approval. The leading opportunity lies in the growth of home-based and point-of-care testing, with self-collection kits and micro-sampling tools extending the market beyond traditional clinical settings into telehealth and remote monitoring. Finally, the main challenge is pricing pressure, as many collection tubes, needles, and syringes are treated as commoditized consumables by large hospital purchasing networks, squeezing manufacturer margins.
Segmentation Highlights
By product, blood collection tubes lead with about 48% share, given their central role in sample preservation and diagnostic accuracy. Needles and syringes follow at roughly 37%, driven by continued reliance on manual venipuncture and a shift toward safety-engineered, retractable designs. The remaining share belongs to lancets, micro-collection kits, and blood bag systems, which are gaining ground in pediatric, home-testing, and donation applications.
By method, manual collection still dominates at approximately 65% of the market, reflecting its cost-effectiveness and flexibility across diverse clinical settings, while automated collection holds about 35%, concentrated in blood banks and plasma centers where high-volume, traceable extraction is valued.
By end user, hospitals and clinics represent the largest segment at roughly 44%, due to consistently high patient throughput and early adoption of advanced collection technologies. Diagnostic and pathology centers follow at about 31%, supported by the expansion of private lab chains and preventive health checkups. Blood banks account for around 18%, driven by transfusion and plasma-therapy demand, while research labs, clinical trials, and home-based testing make up the remaining share.
Competitive Landscape
The report identifies Becton, Dickinson and Company (BD) and Terumo Medical Corporation as the top two players by market share, at approximately 32% and 18% respectively. Other notable companies named include Medtronic, Haemonetics Corporation, Fresenius SE & Co. KGaA, Nipro Medical Corporation, FL MEDICAL s.r.l., and Greiner Bio-One International GmbH. Recent industry developments cited include next-generation safety needles with dual-shield protection, expanded automated plasma collection systems, eco-friendly tube materials, digital sample-tracking integration, and growth in micro-sampling and home collection kits.
Outlook
Overall, the report positions the blood collection devices market as a stable, recurring-demand sector with strong long-term investment appeal, particularly for companies focused on safety innovation, automation, and decentralized/home-based testing models. Emerging economies are flagged as a significant growth frontier as healthcare systems there expand diagnostic coverage and screening infrastructure.